H ost cells are equipped with sophisticated mechanisms to prevent or inhibit viral infection. HIV-1 replication, for example, is targeted by a plethora of restriction factors including APOBEC3, TRIM5α, tetherin, SAMHD1, GBP5 and MX2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Although these factors may suppress HIV-1 replication at various steps through multiple independent mechanisms, they are usually counteracted or evaded by the virus. Another characteristic shared by many host restriction factors is their inducibility by type-I interferons (IFNs), which play a pivotal role in the host defence against viral infection 11, 12 . In search of novel effective antiretroviral mechanisms, nucleic-acid-binding proteins are of particular interest since they are not only important regulators of antiviral gene expression, but may also act as direct effectors of the antiviral immune response 13, 14 . Furthermore, they may modulate sensing of viral infection by binding to and/or degrading viral RNA or DNA species or by directly acting as pattern recognition receptors. One example of a nucleic-acid-binding protein with antiviral activity is the zinc-finger antiviral protein (ZAP). Initially, ZAP was shown to degrade mouse leukaemia virus (MLV) RNA by recruiting the exosome complex 15, 16 . ZAP recognizes RNA sequences enriched in CG dinucleotides, which are suppressed in the genomes of HIV-1 and many other vertebrate viruses 17 . As a result, HIV-1 engineered to contain a higher number of CG dinucleotides is more sensitive to ZAP than the respective parental virus. Another example of an antiviral nucleic-acid-binding protein is SAMHD1. This deoxyribose nucleoside 5' triphosphate (dNTP) triphosphohydrolase blocks HIV-1 reverse transcription in myeloid cells and resting T cells by depleting cellular dNTP pools 9, 10, 18 . Finally, the endoribonuclease regnase-1 (also known as MCPIP1) has been suggested to degrade retroviral messenger RNAs 19 . Given the large number of human RNA-binding proteins identified in recent studies 20, 21 , it seems highly likely that additional RNA-binding proteins with key roles in antiviral immunity remain to be discovered. As the example of SAMHD1 illustrates 22, 23 , some of these restriction factors might be preferentially active in resting CD4
+ T cells and play a role in the establishment and maintenance of latent HIV-1 reservoirs.
To discover novel restriction factors targeting viral RNA, we screened a collection of cellular proteins containing various RNAbinding domains for antiretroviral activity.
Results
Identification of N4BP1 as a host factor inhibiting HIV-1. To identify as-yet-unknown host restriction factors suppressing HIV-1 replication by binding to viral RNA, we selected 62 expression plasmids from Mammalian Gene Collection clones encoding proteins harbouring at least one RNA-binding domain, such as CCCH-or CCHC-type zinc fingers, KH domains or RNase folds (see Supplementary Table 1) , since proteins harbouring these domains may be involved in the suppression of HIV-1 17, 19 . We co-transfected HEK293T cells with the infectious HIV-1 NL4-3 molecular clone and the 62 expression plasmids, and determined the infectious HIV-1 yield in the culture supernatants by infecting TZM-bl indicator cells 48 h post-transfection. Of the 62 proteins analysed, NEDD4-binding protein 1 (N4BP1) was the most potent inhibitor, decreasing infectious HIV-1 NL4-3 production by >20-fold (Fig. 1a) . Immunoblot analysis of cells producing HIV-1 NL4-3 or the primary HIV-1 isolate AD17 revealed that N4BP1 expression decreased the expression of viral Env and Gag proteins in a dose-dependent manner (Fig. 1b) . Analysing a broader panel of primate lentiviruses, including transmitted/founder and chronic control HIV-1 strains, we found that N4BP1 reduced the infectious yield of all HIV-1, HIV-2 and SIVcpz strains examined ( Fig. 1c and Supplementary Fig. 1 ). Thus, N4BP1 is a broad and potent inhibitor of evolutionarily diverse primate lentiviruses.
N4BP1 is IFN-inducible and restricts HIV-1 infection in human T cells.
Since antiretroviral host restriction factors are frequently inducible by IFN and virus infection, we examined whether the expression of N4BP1 is IFN-inducible in T cells. IFN-α stimulation of Jurkat T cells increased N4BP1 expression at both the mRNA and protein level (Fig. 2a,b) . Similarly, N4BP1 expression was induced about threefold by IFN-α stimulation in CD4 + T cells from healthy human donors (Fig. 2c) . Notably, all 12 human IFN-α subtypes, but not interleukin-27 (IL-27), increased N4BP1 protein levels by about two-to fourfold in primary CD4 + T cells ( Supplementary  Fig. 2a,b) . Furthermore, HIV-1 NL4-3 infection induced the expression of mRNAs encoding IFN-β, N4BP1 and the IFN-inducible proteins tetherin (also known as BST-2) and ISG15 in Jurkat cells (Fig. 2d ). N4BP1 gene expression was also significantly upregulated in the spleens of HIV-1-infected humanized mice (Fig. 2e) . Collectively, these data show that N4BP1 is a type-I IFN-and HIV-1-inducible protein with potent anti-HIV-1 activity. Table 1 ) encoding putative RNA-binding proteins. At 48 h post-transfection, the cell culture supernatants were collected and used to infect TZM-bl reporter cells to determine the infectious virus yield. The data values are from two technical replicates. RLU, relative light units. b, HEK293T cells were transfected with either pNL4-3 or pAD17 together with increasing amounts of N4BP1 expression plasmid. Expression of HIV-1 Env and Gag, and N4BP1 in cell lysates as well as Gag p24 in the culture supernatants, was determined by immunoblot analysis at 48 h post-transfection. β-actin was used as the loading control. The upper panel shows the infectious virus yield relative to the empty vector control determined by the TZM-bl reporter assay. n = 3 biological replicates. Individual points and means ± s.d. are shown. c, HEK293T cells were co-transfected with proviral clones of HIV-1 together with increasing amounts of vector expressing N4BP1. At 48 h post-transfection, a TZM-bl reporter assay was performed to measure the production of infectious virus in supernatants. The infectious virus yield relative to the empty vector control is shown as the mean ± s.d of biological replicates (n = 3). TF, transmitted founder virus; CC, chronic control virus; 6-mo, virus isolated 6 months post-infection. P values were calculated using unpaired two-tailed Student's t-test. *P < 0.05; ***P < 0.005. The infectivity of HIV-1 in the culture supernatants was measured by TZM-bl assay. P values were calculated using unpaired two-tailed Student's t-test. *P < 0.05; **P < 0.01; ***P < 0.005.
To determine whether endogenous N4BP1 restricts HIV-1 in human T cells, we used the CRISPR-Cas9 system to generate seven Jurkat cell lines lacking N4BP1 expression (Fig. 2f, left panel) . HIV-1 replicated with faster kinetics in all seven N4BP1-deficient (knockout (KO)) cell lines compared to Cas9-expressing control cells in response to HIV-1 infection (multiplicity of infection (MOI) 0.01) (Fig. 2f, right panel) . Reconstitution of N4BP1 expression via a doxycycline (Dox)-inducible Tet-on system (Fig. 2g, left panel) rescued inhibition of HIV-1 replication (Fig. 2g, right panel) . Notably, growth, apoptosis rates and global protein synthesis were not altered between control and N4BP1-KO Jurkat cells without HIV-1 infection ( Supplementary Fig. 3a-c) . Furthermore, N4BP1 deficiency did not affect the expression of a set of host genes such as IFNB and NFKBIA (Supplementary Fig. 4a) . Consistently, the expression of IκBα, tubulin-α and GAPDH proteins was not different between control and N4BP1-KO Jurkat cells ( Supplementary Fig. 4b ), suggesting that the anti-HIV-1 effect of N4BP1 is direct and not mediated by the regulation of host genes. In agreement with the results of N4BP1-KO cells, short interfering RNA (siRNA)-mediated knockdown of N4BP1 in Jurkat cells ( Supplementary Fig. 5a ) resulted in a marked increase in viral RNA expression 72 h after infection with HIV-1 NL4-3, without significantly affecting IFNB expression levels ( Supplementary Fig. 5b,c) .
Conversely, we also generated four Jurkat cell clones stably overexpressing N4BP1 or a control vector (Fig. 2h, left panel) . N4BP1 overexpression fully prevented HIV-1 replication at a low MOI (0.001) (Fig. 2h, central panel) . Even at a higher MOI (0.01), N4BP1 overexpression prevented or substantially delayed HIV-1 replication (Fig. 2h, right panel) . Furthermore, the expression of viral RNAs including tet/rev, vif and gag was suppressed in N4BP1-overexpressing Jurkat cells ( Supplementary Fig. 5d,e ). These results demonstrate that N4BP1 restricts HIV-1 replication in human T cells.
Since two out of four N4BP1-overexpressing Jurkat cell clones allowed delayed but detectable replication of HIV-1 (Fig. 2h) , we examined whether N4BP1 expression was altered in these cells following HIV-1 infection. To avoid artefacts due to differences in viral replication and spread of infection, we used an env-deficient (Δenv) VSV-G-pseudotyped HIV-1 NL4-3 construct ( Supplementary  Fig. 5f ). Consistent with the results obtained with replicationcompetent HIV-1, production of Gag was suppressed in N4BP1-overexpressing cells compared to control cells in single-cycle infection. Notably, however, N4BP1-mediated inhibition of Gag expression was less pronounced at a higher MOI, suggesting that high amounts of HIV-1 may saturate the inhibitory effect of N4BP1. Furthermore, HIV-1 infection did not reduce N4BP1 expression levels ( Supplementary Fig. 5f ).
N4BP1 restricts HIV-1 in primary macrophages. IFN-α induced N4BP1 mRNA and protein expression not only in T cells (Fig. 2a-c) but also in THP-1-derived macrophage-like cells (Fig. 3a,b) . In addition, we found that N4BP1 is constitutively expressed in primary human monocyte-derived macrophages (MDMs) and further upregulated by IFN-α stimulation (Fig. 3c-e) . To examine the antiretroviral activity of N4BP1 in primary macrophages, we knocked down N4BP1 using three different siRNAs (Fig. 3f) before infecting the cells with the macrophage-tropic HIV-1 strain AD8. The three N4BP1-specific siRNAs increased the infectious HIV-1 AD8 yield by 6.5-, 10.8-and 2.6-fold, respectively, at day 3 and by 16.2-, 14.8-and 4.3-fold by day 6 post-infection (Fig. 3g) . Thus, N4BP1 restricts HIV-1 in both CD4
+ T cells and macrophages.
N4BP1 degrades HIV-1 RNA. To decipher the molecular mechanisms underlying the antiviral effect of N4BP1, we investigated whether its inhibitory activity is limited to HIV-1 and related primate lentiviruses. Overexpression of N4BP1 in HEK293T cells also inhibited MLV (genus Gammaretrovirus) and human foamy virus (HFV; genus Spumavirus) (Fig. 4a) . However, N4BP1 failed to suppress influenza A virus mRNA expression in HEK293T cells ( Supplementary Fig. 6a ). Furthermore, N4BP1 overexpression did not reduce production of infectious influenza A virus in HEK293T cells ( Supplementary Fig. 6b ), arguing against a general and unspecific effect of N4BP1 on viral RNA expression. Since N4BP1 reduces both HIV-1 mRNA and protein expression levels, we analysed whether it affects proviral transcription via the long terminal repeat (LTR) using a reporter system expressing luciferase under the control of the viral LTR promoter. While NL4-3 Δenv induced reporter gene expression, co-expression of N4BP1 failed to suppress HIV-1 LTR-mediated gene expression ( Supplementary  Fig. 7a ). In contrast, N4BP1 suppressed HIV-1 expressed under the control of the CMV promoter (pCMV259), but did not affect EGFP expression from the same promoter ( Supplementary Fig. 7b,c) . Together, these results suggest that N4BP1 suppresses HIV-1, but not EGFP, at a post-transcriptional level.
N4BP1 was originally identified as a target of the E3 ubiquitin ligase NEDD4, resulting in its proteasomal degradation in the nucleolus and promyelocytic leukaemia (PML) bodies 24, 25 . N4BP1 harbours a potential nuclease domain in addition to two KH domains, which represent canonical single-stranded nucleic-acidbinding domains (Fig. 4b) 
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. The nuclease domain of N4BP1 is highly conserved among mammalian species and structurally predicted to form a catalytic pocket with conserved aspartic acids (Fig. 4c) . Using a subgenomic sequence of HIV-1 NL4-3 as substrate, we found that recombinant N4BP1 degrades viral RNA in vitro ( Fig. 4d and Supplementary Fig. 8a ). Structural modelling of the human N4BP1 RNase domain revealed that it harbours a catalytic centre whose structure and primary amino-acid sequence is similar to that of Regnase-1 ( Fig. 4e and Supplementary Fig. 8b) . A point mutation of Asp 623, which is predicted to be an essential part of the catalytic centre, to asparagine (D623N) fully abrogated the RNase activity of N4BP1 (Fig. 4d) . Importantly, structural modelling suggests that the D623N mutation does not alter the overall structure of the RNase domain of N4BP1 (Fig. 4e) .
Consistently, northern blot analysis showed that N4BP1 reduces unspliced, singly spliced and multi-spliced viral mRNAs in an RNase-activity-dependent manner, while ribosomal RNA was not affected (Fig. 4f) . In contrast, incoming viral RNA was not degraded as knockdown of N4BP1 did not significantly alter the amount of early or late reverse transcriptase (RT) products or the amount of integrated proviral DNA in infected Jurkat cells ( Supplementary  Fig. 8c ).
To test whether N4BP1 directly binds HIV-1 RNA, we performed an RNA immunoprecipitation (RIP) assay using the N4BP1 D623N mutant, in which the RNA-protein interaction is expected to be stable due to the lack of RNase activity. The RIP-quantitative PCR (qPCR) assays revealed that the N4BP1 D623N mutant binds several HIV-1 mRNA species including splice products expressing Tat/Rev, Vif and Gag (Fig. 4g ). In agreement with RNase-dependent restriction, wild-type (WT) N4BP1, but not the catalytically inactive mutant D623N, suppressed viral protein expression ( Fig. 4h and Supplementary Fig. 8d ) and infectious HIV-1 yield (Fig. 4i ) without affecting cell viability ( Supplementary Fig. 8e,f) . Collectively, these data demonstrate that N4BP1 restricts HIV-1 replication by binding and degrading viral mRNA species.
MALT1 degrades N4BP1 in T cells following TCR-mediated activation.
Antiretroviral restriction factors are often counteracted by HIV-1 accessory proteins. N4BP1, however, inhibited WT HIV-1 NL4-3 and a mutant lacking all four accessory proteins (NL4-3 Δ4) with similar efficiencies (Supplementary Fig. 9 ). Thus, we next examined N4BP1 expression levels in activated CD4
+ T cells that are highly permissive for HIV-1 replication and resting T cells thought to represent the main reservoir of latent HIV-1. Interestingly, N4BP1 protein levels were drastically decreased in primary CD4 + T cells activated with phorbol 12-myristate 13-acetate (PMA) plus ionomycin or by treatment with anti-CD3/CD28 antibodies, but not with IFN-γ or IL-2 ( Fig. 5a ). Kinetic analysis revealed that N4BP1 levels started to decrease at 0.5 h after PMA/ionomycin stimulation and remained undetectable for at least 8 h (Fig. 5b) . Notably, N4BP1 mRNA levels were not markedly affected by PMA/ionomycin treatment ( Supplementary Fig. 10a ). In support of N4BP1 protein degradation, an ~72 kDa cleavage product appeared in PMA/ ionomycin-treated cells (Fig. 5b ) just above nonspecific bands (65 kDa and 40 kDa) that is also present in N4BP1-KO cells (Fig. 2f) .
Although N4BP1 was reported to undergo NEDD4-mediated polyubiquitylation 25 , proteasome inhibitor treatment did not prevent PMA/ionomycin-mediated degradation of N4BP1 ( Supplementary  Fig. 10b ). Further experiments revealed that PMA alone, but not ionomycin, is sufficient to decrease N4BP1 levels ( Supplementary  Fig. 10c ). Similar to T-cell receptor (TCR) signals, PMA activates signalling pathways via the CARMA1-BCL10-mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) signalosome 27 . MALT1 is known to cleave the RNA-binding proteins eRgnase-1 and Roquin 28, 29 . Consistent with a previous report, overexpression of Regnase-1 also suppressed infectious HIV-1 NL4-3 production, whereas the expression of Roquin-1 or -2 had no inhibitory effect 10,000 P = 0.028 were determined by immunoblotting. e, The N4BP1 expression levels were normalized to β-actin levels and the unstimulated sample was set to 100%. n = 3 biological replicates. Individual points and means ± s.d. are shown. f, Representative immunoblot analysis of human MDMs transfected with control siRNA or three different N4BP1-specific siRNAs (left panel). The N4BP1 expression levels were normalized to β-actin levels and the control siRNA sample was set to 100%. The data are shown as the mean values ± s.d. of five independent experiments. g, Human MDMs treated with control or N4BP1-specific siRNA (nos. 18638-18640) were infected with HIV-1 AD8 and analysed for infectious virus production at 3 (n = 9) and 6 (n = 7) days post-infection (dpi). Shown are mean percentages ± s.d. relative to those detected in control cells (100%). P values were calculated using unpaired two-tailed Student's t-test. *P < 0.05; **P < 0.01; ***P < 0.005. as assessed by TZM-bl reporter assay. The infectious virus yield relative to the empty vector control is shown. n = 3 biological replicates. Individual points and means ± s.d. are shown. P values were calculated using unpaired two-tailed Student's t-test. *P < 0.05; **P < 0.001; ***P < 0.005; NS, not significant. ), PMA (50 ng/ml) plus ionomycin (500 nM) or anti-CD3/CD28 antibody-coated beads for 24 h. b, The N4BP1 protein levels in Jurkat cells stimulated with PMA plus ionomycin for the indicated periods of time were determined by immunoblotting. c, Immunoblot analysis of N4BP1 in parental or MALT1-KO Jurkat cells stimulated with PMA plus ionomycin for 1 h. d, The N4BP1 protein levels in Jurkat cells stimulated with PMA plus ionomycin for 1 h with zVAD-fmk, a pan-caspase inhibitor (10 μM), or zVRPR-fmk, a MALT1 inhibitor (100 μM). e, Schematic representations of N4BP1 and its mutants. The epitope of the N4BP1-specific antibody used in the present study is indicated. f, The apparent molecular weights of N4BP1 and its truncation mutants were determined by immunoblotting of transfected HEK293T cells. g, A sequence-logo plot representing the amino-acid frequencies at positions 1 to 7 in 16 previously identified MALT1-cleavage sites (Supplementary Fig. 10e ). h, Localization of the potential MALT1-cleavage site in N4BP1. Multiple sequence alignment of different N4BP1 orthologues. Asterisks indicate fully conserved residues and full-stops indicate conservation between groups of weakly similar properties. i, Cleavage of N4BP1 in HEK293T cells transfected with the indicated N-terminally Flag-tagged N4BP1 variants. Degradation of N4BP1 and emergence of the 72 kDa cleavage product were monitored by immunoblot with an anti-Flag antibody. j, N4BP1 levels were determined by immunoblotting of Jurkat cells transfected with an empty vector or expression plasmids for Flag-N4BP1. k, HEK293T cells were co-transfected with pNL4-3 and vectors expressing WT or mutant N4BP1. At 48 h post-transfection, a TZM-bl reporter assay was performed. The infectious virus yield relative to the empty vector control is shown. n = 3 biological replicates. Individual points and means ± s.d. are shown. P values were calculated using unpaired two-tailed Student's t-test. ***P < 0.005. (Supplementary Fig. 10d ). We therefore hypothesized that N4BP1 might also be cleaved by MALT1. Indeed, KO of MALT1 in Jurkat cells abrogated degradation of N4BP1 in response to stimulation (Fig. 5c) . Furthermore, the MALT1 inhibitor zVRPR-fmk, but not a pan-caspase inhibitor zVAD-fmk, suppressed cleavage of N4BP1 (Fig. 5d) . Thus, the protease activity of MALT1 is essential for N4BP1 cleavage following T-cell activation.
MALT1 cleaves N4BP1 at Arg 509. The appearance of an ~72 kDa cleavage product (Fig. 5b) suggested that the MALT1-cleavage site(s) is located in the central region of N4BP1, between the KH and RNase domains (Fig. 5e) . Thus, we generated a series of carboxy-terminally truncated variants to determine the exact position of the cleavage site (Fig. 5e) . Immunoblot analysis revealed that the electrophoretic mobility of an N4BP1 mutant comprising the amino-terminal 500 amino acids was close to that of MALT1-cleaved N4BP1 (Fig. 5f ). MALT1 specifically cleaves after arginine residues 27 , and analysis of previously identified MALT1 substrates revealed a putative [S/P]-R-G consensus target sequence for this protease ( Fig. 5g and Supplementary Fig. 10e ). N4BP1 harbours a highly conserved SRG motif at positions 508-510 (Fig. 5h) , and R509A mutant N4BP1 was not cleaved by MALT1 expressed together with BCL10 (Fig. 5i) . Furthermore, PMA/ionomycin stimulation of Jurkat cells induced cleavage of WT Flag-N4BP1, while the Flag-N4BP1 R509A mutant was resistant to cleavage (Fig. 5j) . Notably, mutation of R509A rendered N4BP1 resistant to MALT1 cleavage without impairing its antiviral activity (Fig. 5k) .
Degradation of N4BP1 promotes reactivation of latent HIV-1.
Degradation of N4BP1 by MALT1 might be involved in the reactivation of latent HIV-1 by T-cell activation. To investigate this possibility, we first examined N4BP1 expression in three different human T-cell lines harbouring latent HIV-1 proviruses [30] [31] [32] . N4BP1 was constitutively expressed and downmodulated following PMA stimulation in all cell lines tested ( Supplementary Fig. 11a-c) . As expected, PMA-induced degradation of N4BP1 was abrogated in MALT1-KO JNLGFP, J-Lat10.6 and J-Lat5A8 cells (Fig. 6a,b and Supplementary  Fig. 11d ). Thus, MALT1 is required for PMA-induced degradation of N4BP1 in latently HIV-1-infected T cells. MALT1-KO JNLGFP, J-Lat10.6 and J-Lat5A8 cells showed significantly lower levels of HIV-1 reactivation than control cells in response to PMA stimulation (Fig. 6c,d and Supplementary Fig. 11e ). After induced expression of N4BP1 in J-Lat10.6 and JNLGFP cells by a Tet-On system, WT but not R509A N4BP1 was degraded in response to PMA stimulation (Fig. 6e,f) . Intriguingly, the MALT1-resistant N4BP1 R509A mutant suppressed the reactivation of J-Lat10.6 and JNLGFP cells more efficiently than WT N4BP1 as examined by the changes in HIV-1 p24 levels in the culture supernatants (Fig. 6e,f) . We further established N4BP1-KO JNLGFP cells (Fig. 6g) , and reconstituted them with WT N4BP1 or the R509A mutant thereof using the inducible Tet-On system (Fig. 6h) . Consistent with the overexpression data, JNLGFP cells reconstituted with R509A N4BP1 potently suppressed reactivation of HIV-1, whereas cells reconstituted with WT N4BP1 failed to do so (Fig. 6h,i) . Thus, inactivation of N4BP1 by MALT1 supports latency reversal following activation of latently HIV-1-infected T cells (Supplementary Fig. 12 ).
Discussion
Our study demonstrates that HIV-1 latency and reactivation are controlled by N4BP1 at the post-transcriptional level. Notably, two mechanisms may contribute to the maintenance of viral latency by N4BP1. First, N4BP1 generally degrades spliced and unspliced HIV-1 transcripts, thereby preventing their translation into viral proteins and progeny virion formation. Second, N4BP1 may continuously keep HIV-1 Tat levels below the threshold required for reactivation and efficient transcription of viral genes. Intriguingly, N4BP1 is rapidly inactivated by MALT1 in response to stimuli inducing HIV-1 reactivation, indicating that changes in MALT1 activation levels regulate HIV-1 reactivation. Thus, manipulation of MALT1 activity may be a promising approach to control HIV-1 latency and reactivation. Notably, treatment with the MALT1 inhibitor MI-2 has previously been shown to induce death of latently HIV-1-infected cells, and death rates were further increased by PMA stimulation 33 . However, the specificity of the MALT1 inhibition and the MALT1 targets involved in this process remained unclear. Thus, further studies are required to decipher the suitability of MALT1 as a target for therapeutic intervention.
An important open question is how N4BP1 specifically recognizes retroviral RNA, without degrading, for example, influenza A virus or ribosomal RNAs. Given that multi-spliced HIV-1 RNA (encoding Tat and Rev) as well as singly or unspliced viral mRNAs are degraded, N4BP1 might target motifs or structures in unspliced viral mRNA, the tat/rev encoding region or end modifications found in all three mRNA classes. The frequency of CG dinucleotides is markedly suppressed in the genomes of HIV-1 as well as other vertebrate viruses, thereby attenuating ZAP-mediated restriction 17 . Given that N4BP1 suppresses various lenti-and retro-viruses including HIV-1, sequence motif(s) other than CG dinucleotides could be recognized by N4BP1.
N4BP1 is localized in the nucleus especially in the nucleolus and/ or PML bodies 25 . Intriguingly, HIV-1 transcripts are specifically re-localized into nucleoli for viral gene expression 34 . In addition, latent HIV-1 was reported to co-localize with PML bodies, with PML binding to the latent HIV-1 LTR promoter 35 . Degradation of PML led to the activation of viral transcription together with the release of histone methyltransferase G9a 35 . Given that HIV-1 RNA is suppressed by N4BP1, it is tempting to speculate that N4BP1 co-transcriptionally degrades viral mRNA in PML bodies, thereby contributing to the maintenance of latency. Although MALT1 is mainly present in the cytoplasm, this protein harbours a nuclear export signal, and is reported to shuttle between the nucleus and cytoplasm 36 . Thus, MALT1 might cleave N4BP1 in the nucleus. Our data suggest that N4BP1 is not directly counteracted by HIV-1 accessory proteins. However, it is possible that HIV-1 has evolved means to evade N4BP1. Furthermore, expression of N4BP1 was diminished in T cells stimulated with PMA/ionomycin or via TCR-CD3/ CD28 ligation. Considering that HIV-1 replicates efficiently in activated but not in quiescent CD4 + T cells, it is tempting to speculate that reduction of N4BP1 facilitates HIV-1 replication in activated T cells. We discovered that cleavage and inactivation of N4BP1 in T cells is mediated by the protease MALT1 and identified Arg 509 as its cleavage site. Previously described MALT1 substrates include host mRNA regulators such as Regnase-1 and Roquin. These proteins are critical for controlling immune reactions as they destabilize host mRNAs encoding proinflammatory cytokines and proteins involved in T-cell activation 37, 38 . It is intriguing to explore the function of N4BP1 in the control of immune responses and future studies will uncover the functional roles of N4BP1 in regulating host mRNAs in vivo.
A recent study determining type-I interferomes of fibroblasts in multiple vertebrate species identified 62 evolutionarily conserved interferon-stimulated genes (ISGs) 12 . Interestingly, N4BP1 was also among these core ISGs. Following IFN-α stimulation, N4BP1 suppresses HIV-1 infection by inducing its expression and/or altering its RNase activity. Furthermore, the MALT1-cleavage site and the RNase domain are conserved among the N4BP1 orthologues of different mammalian species, consistent with IFN-inducibility. These notions imply that the function of N4BP1 in antiviral immunity is conserved among different species. Given that human N4BP1 suppresses a variety of retroviruses, but not influenza A virus, it is tempting to speculate that N4BP1 might have an ancestral function in specifically controlling retroviral infection. Furthermore, it will be interesting to explore whether N4BP1 is involved in the posttranscriptional silencing of endogenous retroviruses. ) for 24 h. The levels of Gag p24 in the supernatants were quantified and indicated as the percentage of Dox (−) controls (values between blots). g, Immunoblot analysis of N4BP1 in control and N4BP1-KO JNLGFP cells generated by the CRISPR-Cas9 system. β-actin was used as the loading control. h,i, N4BP1-KO JNLGFP cells were inducibly reconstituted with WT or R509A N4BP1 by the Tet-on system via Dox treatment, followed by stimulation with PMA (10 ng ml ) for 24 h. Cell lysates and culture supernatants were collected and immunoblot analysis was performed to determine the expression of N4BP1, Gag and β-actin proteins (h). The ratio of p24 expression in the culture supernatants between Dox (−) controls and Dox (+) WT or R509A-N4BP1-expressing cells examined in h is shown in i (n = 3). Individual points and means ± s.d. are shown. Sup, supernatant. P values were calculated using unpaired two-tailed Student's t-test. **P < 0.001; ***P < 0.005.
In this study, we identified N4BP1 as an HIV-1 restriction factor by screening proteins that harbour potential RNA-binding domains. As our screening approach did not include all RNA-binding proteins, it is possible that additional anti-retroviral RNA-binding factors remain to be discovered. Furthermore, an overexpressionbased screening approach may fail to identify antiviral proteins that are endogenously expressed to high levels, if overexpression does not further increase their abundance. Therefore, further studies are required to elucidate the role of RNA-binding proteins in restriction of HIV-1 (for example, by using more complete sets of RNA-binding proteins and/or loss-of-function screening systems).
In summary, we identified N4BP1 as an RNase that functions as an antiretroviral restriction factor by degrading various HIV-1 mRNA species. Although further studies are required to precisely define the molecular mechanisms underlying target RNA recognition by N4BP1, our findings clearly demonstrate that N4BP1 is a potent effector of type-I IFN-mediated anti-HIV-1 activity. 41 and pAD17 (catalogue no. 12423) 42 were obtained through the NIH AIDS Reagent Program from B. Hahn (University of Pennsylvania). The SIVcpz molecular clone MB897 43 , as well as HIV-1 pCH058 (6-month), pCH077 (6-month), pCH440, pCH200v2, pCH534 and CH042 were kindly provided by B. Hahn [44] [45] [46] . The HIV-1 AD8 infectious molecular clone was obtained from C. Collins (UCSD, San Diego) and has been described previously 47 . The Moloney leukaemia virus strain pMLV48 was kindly provided by K. Atsushi (Nagoya Medical Center). The HFV strain HSRV13 was kindly provided by D. Russel (University of Washington). pCMV259 was kindly provided by J. Sakuragi (Osaka University) 48 . At 48 h post-transfection, culture supernatants were collected, then filtered and stocked as a viral solution. For the replication assay, empty vector or N4BP1-expressing Jurkat cells were seeded at 2 × 10 5 cells in 48-well plates. Then, they were inoculated with HIV-1 NL4-3. Primary CD4 + T cells were isolated from human blood from three healthy donors by Ficoll Paque gradient centrifugation and negative selection using the RosetteSep Human CD4 + T cell Enrichment Cocktail (Stem Cell Technologies) and cultured in RPMI1640. Monocytes were separated from peripheral blood mononuclear cells (PBMCs) by plastic adherence and differentiated into MDMs using AB serum (10%) and macrophage colonystimulating factor (R&D Systems; 15 ng ml −1 ). Primary human macrophages were differentiated from human PBMCs from 3 healthy donors. PBMCs were seeded onto the plate in serum-free RPMI-1640 for 3 h at 37 °C. Non-adherent cells in the supernatants were discarded and adherent monocytes were cultured in RPMI-1640 with 10% FCS and macrophage colony-stimulating factor (15 ng ml , PeproTech) for 6 days.
Methods
Generation of virus stocks. HEK293T cells were sown in 6-well plates and transfected with proviral HIV-1 DNA (5 µg) at a confluence of 70-80% using a standard calcium phosphate transfection protocol. For mock infection controls, HEK293T cells were treated with transfection reagents alone. Supernatants were collected 40 h post transfection.
Infectivity assay. Infectious HIV-1 released into the cell culture supernatant was quantified by infection of TZM-bl reporter cells. Appropriate virus dilutions were added to 5 × 10 3 TZM-bl cells per well of a 96-well plate. The cells were collected 48 h post-infection, and a β-galactosidase assay was performed using the Galacto-Star Mammalian Reporter Gene Assay System (Applied Biosystems) according to the manufacturer's protocol. Galactosidase activity was quantified as relative light units per second using a 1420 ALBOSX multilabel counter (Perkin Elmer).
Plasmid construction. The cDNA of human N4BP1 was ligated into pFlag-CMV2 (Invitrogen), pEFs-Flag-SBP or CSII-CMV-MCS-IRES2-Bsd for mammalian cell expression. The site-directed mutant expression vectors including pFlag-CMV2 N4BP1 D623N or R509A and pEFs-Flag-SBP D623N were generated using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent). Deletion mutant cDNAs encoding amino acids 1-700 (Δ1), 1-600 (Δ2), 1-500 (Δ3) and 1-400 (Δ4) of N4BP1 were inserted into the pFlag-CMV2 vector. A lentiviral packaging plasmid, CSII-CMV-MCS-IRES2-Bsd, was provided by Miyoshi at Keio University. N4BP1 and its R509A mutant were inserted into the pInducer20, a Tet-on Dox-inducible lentiviral expression plasmid.
Immunoblotting. HEK293T cells were seeded in 12-well plates. Cell-free viral solutions were pelleted by ultracentrifugation of the culture supernatants at 40,000 r.p.m. for 1 h at 4 °C by using a TL-100 (Beckman), and then lysed in the immunoblot lysis buffer. Cell lysates were mixed with 3× loading sample buffer supplemented with 15% β-mercaptoethanol. Protein samples were resolved on a 5-20% NuPAGE gel (Invitrogen). Proteins were transferred from the SDS-PAGE gel to Immobilon-PVDF membranes (Merck Millipore). Proteins were labelled with antibodies against HIV-1 Env (1:2,000; 16H3, catalogue no. 12559, NIH AIDS Research and Reference Reagent programme), p24 (1:2,000, polyclonal; ViroStat), Vif (1:2,000; no. 319; NIH AIDS Research and Reference Reagent programme), Nef (1:2,000; 3D12, ThermoFisher), Vpr (1:2,000; 8D1, Cosmo Bio), Vpu (1:2,000; no. 969, NIH AIDS Research and Reference Reagent programme), Flag (1:1,000; monoclonal; F7425, Sigma, or polyclonal; F7425, Sigma), mouse IgG isotype control (1:1,000; no. 31903, ThermoFisher), β-actin (1:1,000; polyclonal; sc-1615, Santa Cruz), MALT1 (1:1,000; no. 2494, Cell Signaling Technology), GAPDH (1:1,000; sc-47724, Santa Cruz), α-tubulin (1:1,000; T9026, Sigma), IκBα (1:1,000; C-21, Santa Cruz), GFP (1:1,000; ab290, Abcam) and N4BP1 (1:2,000, ab197079, Abcam). The anti-N4BP1 antibody recognizes the N-terminal portion of N4BP1 (amino acids 250-300). ). Jurkat cells were stimulated with 50 ng ml −1 phorbol 12-myristate 13-acetate (PMA: Sigma Aldrich) with or without 500 nM ionomycin (Sigma Aldrich). Human primary CD4 + T cells were stimulated with IFN-α subtypes (50 ng ml ) or anti-CD3/CD28 beads (Dynabeads Human T-Activator CD3/CD28, Gibco) for 24 h. JNLGFP, J-Lat5A8 and J-Lat10.6 cells were stimulated with 10-50 ng ml −1 PMA for 24 h. zVRPR-fmk (Enzo Life Sciences), a MALT1 inhibitor, zVAD-fmk (R&D systems), a pan-caspase inhibitor, and MG132 (Merck Millipore), a proteasome inhibitor, were used at concentrations of 100 μM, 10 μM and 0.001-10 μM, respectively. RNA isolation, RT and qRT-PCR. Total RNA was isolated using Trizol reagent (Invitrogen). Reverse transcription was performed using ReverTra Ace (TOYOBO) according to the manufacturer's instructions. The relative RNA expression levels of IFNB, 18S, N4BP1, tat/rev, vif, gag, HIV-1 total RNA, BST-2, ISG15, MLV gag, SIVcpz gag, HSRV13 gag and influenza A segment 4 (HA) were measured by SYBR Green Real-Time PCR in Applied Biosystems Step One Plus. Viral RNA in supernatants was extracted using the ZR viral RNA kit (ZymoResearch). The sequences of the primers used in qPCR are shown in Supplementary /Jic (NOD/SCID Il2rg null ) mice were obtained from the Central Institute for Experimental Animals (Kanagawa, Japan). The mice were maintained under specific-pathogen-free conditions and were handled in accordance with Regulations on Animal Experimentation at Kyoto University. The study protocol was approved by the Animal Experimentation Committee at Kyoto University. Human CD34
+ haematopoietic stem cells were isolated from human fetal liver as previously described 49 . To generate humanized mice (NOG-hCD34 mice), human fetal liver-derived CD34 + cells (5 × 10 4 to 12 × 10 4 cells) were intrahepatically injected into newborn NOG mice aged 0 to 2 days after X-irradiation (10 cGy per mouse) in an RX-650 X-ray cabinet system (Faxitron X-ray Corporation). Humanized mice were randomly assigned to HIV-1 infection or mock treatment.
Generation of N4BP1-or MALT1-KO cells by the CRISPR-Cas9 system.
N4BP1-KO Jurkat cells were generated by transiently transfecting the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene) with the Neon Transfection System according to the manufacturer's protocol. The N4BP1-coding exon was targeted using the following single-guide RNA (sgRNA) target site: 5′-AGATATAAAAGAAACTACTG-3′. Single clones were obtained by limiting dilution in 96-well U-bottomed culture plates. Control cells were obtained following transfection of the plasmid without sgRNA. For generating MALT1-KO Jurkat cells, cells were delivered with the sgRNA-and Cas9-expressing lentivirus vector (LentiCrispr v2 puro: Addgene) targeting the MALT1-coding sequences; sgRNA1 5′-GCAGTGCATGTAAAAGATGC-3′, sgRNA2 5′-ATTCAGCCAGTGGTCACAGC-3′. Control cells were obtained by transduction of lenticrispr v2 expressing non-targeting control sgRNA; 5′-GGCCGATAATGATCCGACCG-3′. Two days after transduction, cells were cultured with 1 μg ml −1 puromycin for 10 days. KO of N4BP1 or MALT1 was examined by immunoblot analysis.
Establishment of stably N4BP1-expressing cells. Stably N4BP1-expressing Jurkat cells were generated by transfection with CSII Bsd IRES MCS-N4BP1 using the Neon Transfection System. Three days after transfection, N4BP1-expressing cells were selected by culturing them in 10 μg ml −1 blasticidin-containing RPMI-1640 for 14 days. Control cells were prepared by transfecting an empty plasmid. In some experiments, single clones were obtained by limiting dilution in 96-well U-bottomed culture plates. Stably N4BP1-expressing HEK293T cells and control cells were generated by transfection with CSII Bsd IRES MCS-N4BP1 and empty plasmid, respectively. For inducible expression of N4BP1, N4BP1-KO, JNLGFP, N4BP1-KO JNLGFP or J-Lat10.6 cells were prepared by pseudotyped lentivirus vector transduction with pInducer20 vector with or without WT or R509A mutant N4BP1 followed by selection in G418.
siRNA transfection and infection of macrophages and Jurkat cells. On days 7 and 10 of differentiation, MDMs were transfected with N4BP1-specific or nontargeting control siRNA using Lipofectamine RNAiMAX (Life Technologies) followed by infection at day 10. All siRNAs were provided in a lyophilized state by ThermoFisher (nos. 18638, 18639 and 18640) or Eurofins Genomics (nontargeting control: UUCUCCGAACGUGUCCACGUdTdT) and suspended in nuclease-free water to reach a final concentration of 20 μM. siRNA transfection was performed in 12-well plates with 3 technical replicates for each sample. For 1 well, 2.25 μl siRNA was mixed with 150 μl Opti-MEM and 6 μl Lipofectamine RNAiMAX was mixed with 150 μl Opti-MEM. These two solutions were then mixed and incubated at room temperature for 10 min. Afterwards, 300 μl of the mixture was dropped on the well containing 1 ml of cell culture medium. The medium was changed 18 h after each transfection. At 3 and 6 days post infection, macrophage culture supernatants were collected and used to infect TZM-bl reporter cells. To this end, 6,000 TZM-bl cells were sown in 96-well plates and infected in triplicate with cell culture supernatants containing infectious virus. Three days later, infection rates were determined using a galactosidase screen kit (GalScreen-Applied Bioscience) according to the manufacturer's instructions. β-galactosidase activities were quantified as relative light units per second using an Orion Microplate Luminometer. For knockdown in Jurkat cells, cells were transfected with N4BP1-specific siRNA (s18640) or negative control siRNA using NEON according to the manufacturer's protocol. Differentiated human macrophages were transfected with siRNA on days 6 and 8 after isolation. Cells were transfected with N4BP1-specific siRNA (s18638-18640) or negative control siRNA using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer's instructions.
Structure modelling. The PilT N terminus (PIN) RNase domain of human N4BP1 was modelled with the SFAS threading meta server (http://sysimm.ifrec. osaka-u.ac.jp/sfas2/) using human regnase-1 (PDB Identifier 3v32, chain B) as a template. The conservation heatmap was constructed by aligning the top 1,000 hits from the NCBI nr database to human N4BP1 using MAFFT (PMID: 23329690), and computing the sequence identity to human N4BP1. The sequence identity was expressed as a temperature factor in the human N4BP1 model PDB file and displayed in PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC). In vitro RNA cleavage assay. The in vitro RNA cleavage assay has been previously described 39 . Briefly, recombinant N4BP1 protein and in vitro-transcribed 5′-[ 32 P]-labelled viral RNA (tat, rev and nef subgenomic RNA of HIV-1 NL4-3) 50 or a 513 base RNA fragment from the pBluescript vector) were mixed in cleavage buffer (25 mM HEPES, 50 mM potassium acetate, 5 mM DTT, 5 mM magnesium acetate and 0.2 U ml −1 RNasin (Promega)) for 60 min at 37 °C. The cleaved RNA was analysed by denaturing 6% polyacrylamide-TBE-urea gels (Invitrogen) and autoradiography. The sequence used for in vitro transcription and the in vitro cleavage assay is shown in Supplementary Table 3 .
Northern blotting. Using Trizol reagent, total RNA was isolated from HEK293T cells 48 h post-transfection with pNL4-3 together with N4BP1 expression plasmid, D623N or empty plasmid. Extracted RNA was electrophoretically separated, transferred to Hybond-N+ (GE Healthcare), and hybridized with the probe derived from a fragment of pNL4-3.
32 P-labelled probe was generated from the 422-nucleotide XhoI/BamHI restriction fragment in the 3′-UTR of pNL4-3, which is present in all HIV-1 mRNAs. HIV-1 primary RNA transcripts, generated by alternative splicing, were detected as three major bands representing three different sizes.
RNA-immunoprecipitation and qPCR analysis.
HEK293T cells seeded at 3 × 10 6 in 10 cm plates were transfected with 5 μg of pNL4-3 together with 5 μg of a plasmid expressing the N4BP1 D623N mutant. Flag-tagged N4BP1 was immunoprecipitated with an anti-Flag antibody (Sigma) or control mouse IgG isotype controls (Thermo Fisher) 48 h after transfection. N4BP1-interacting HIV-1 RNA was extracted using Trizol, quantified by RT-qPCR and normalized to 18S RNA bound in a nonspecific manner.
Analysis of global protein synthesis. Control and N4BP1-KO Jurkat cells were cultured for one day. As a negative control, some control cells were treated with a protein synthesis inhibitor, cycloheximide (Cayman Chemical), for 30 min. Then the cells were collected, and translating polypeptides were labelled with O-propargyl-puromycin for 30 min at 37 °C followed by staining with 5-FAM azide using the Protein Synthesis Assay kit (Cayman Chemical) according to the manufacturer's instructions. The cells were analysed by Flow cytometry (FACSVerse; BD). The data analysis was performed using FlowJo (LCC).
HIV-LTR reporter gene assay. TZM-bl cells cells were transfected with the pGL3-HIV-LTR-Luc plasmid or pGL3-empty plasmid together with N4BP1 expression plasmid or empty control plasmid. At 24 h post-transfection, cells were lysed and luciferase activities in the lysates were determined using the Dual-Luciferase Reporter Assay System (Promega).
Detection of early RT products, late RT product and integrated proviral DNA. Quantification of HIV-1 early RT (R/U5), late RT (U5/gag) and integrated products by real-time PCR was done by following a published protocol (Suzuki et al., 2003) . Briefly, virus was treated with DNase-I (TAKARA) at a concentration of 20 mg ml −1 in the presence of 10 mM MgCl 2 at room temperature. Heatinactivated (65 °C, 30 min) virus was used as a negative control for infection. Jurkat cells were transfected with N4BP1 or control siRNA. One day after transfection, Jurkat cells were exposed to HIV-1 NL4-3 (MOI 0.1) or heatinactivated HIV-1 at 37 °C for 2 h. Total DNA was isolated 12 h after infection, by using DNeasy Blood & Tissue Kits (QIAGEN) according to the manufacturer's instructions. Early RT products, late RT products and integrated DNA were quantified by real-time PCR.
Influenza infection experiment. HEK293T cells stably expressing N4BP1 or control plasmid were infected with influenza A virus PR8 or WSN strain for 24 h before total RNA or culture media were collected. Total RNA was subjected to qPCR analysis to measure the expression levels of viral mRNA for segment 4 (HA). The viral growth in the culture media was titrated by using plaque assays on Madin-Darby canine kidney cells.
Statistical analysis and reproducibility. Statistical analyses were conducted using Prism 8 (GraphPad, La Jolla, CA, USA) or Excel for Office365. Statistical significance was calculated with an unpaired two-tailed Student's t-test. Data are presented as the mean ± s.d.. A P value of <0.05 was considered statistically significant. The screening of RNA-binding proteins restricting HIV-1 was repeated and the results were confirmed in an independent experiment (Fig. 1a) . The in vivo experiment with humanized mice (Fig. 2e) was performed once. The data for HIV-1 yield in MDMs treated with N4BP1-specific siRNAs (Fig. 3g ) and p24 production comparing between WT or R509A mutant N4BP1-reconstituted JNLGFP cells (Fig. 6h) The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Data collection
Flow cytometry data were collected using BD FACSuite™ software. RT-qPCR data were collected using Applied Biosystems Step One Plus system. Immunoblot data were collected using Amersham Imager 600.
Data analysis
To model human N4BP1 PIN RNA domain, we utilized SFAS threading meta server (http://sysimm.ifrec.osaka-u.ac.jp/sfas2/) using human Regnase-1 (PDB Identifier 3v32, chain B) as a template. All 3D models were visualized using PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.). The Flow cytometry data were analyzed using FlowJo v10 software. Prism 8 (GraphPad, La Jolla, CA, USA) and Excel for Office365MSO to do the graph figures and statistics.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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There is no restriction on data availability. And the data that support the findings of this study are available from the corresponding author upon request.
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Cell line source(s)
NIH AIDS Reagent program. JNLGFP cells were kindly provided by David N Lady in New York University college of dentistry. JLat5A8 cells were kindly provided by Warner C. Greene in Gladstone Institute of Virology and Immunology.
Authentication
Cell lines were obtained from the NIH AIDS Reagent Program and ATCC, or obtained from investigators who generated them. These cell lines have not been authenticated.
Mycoplasma contamination
Cell lines were not tested for mycoplasma.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Animals and other organisms
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Laboratory animals
Mice were maintained under specific-pathogen-free conditions and were handled in accordance with Regulations on Animal Experimentation at Kyoto University. NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic (NOD/SCID Il2rgnull) mice (Ito et al., 2002) were obtained from the Central Institute for Experimental Animals (Kanagawa, Japan). Human CD34+ hematopoietic stem cells (HSCs) were isolated from human fetal liver as previously described (Nakano et al., 2017) . To generate humanized mice (NOG-hCD34 mice), human fetal liver-derived CD34+ cells (5×104 to 12×104 cells) were intrahepatically injected into newborn NOG mice aged 0 to 2 days after X-irradiation (10 cGy per mouse) in an RX-650 X-ray cabinet system (Faxitron X-ray Corporation).
Wild animals
Wild animals were not used.
Field-collected samples
This study does not involve samples collected from the fields.
Ethics oversight
The study protocol was approved by the Animal Experimentation Committee in Kyoto University.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
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Population characteristics
Human participants were 6 healthy donors (3 donors for preparing primary CD4+ T cells and 3 donors for preparing monocytederived macrophages).
Recruitment
Volunteer participants were selected from people in HIV-1 negative and good health condition.
Ethics oversight
The study has been approved by the Kyoto University institutional review board.
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Methodology Sample preparation
Jurkat cells cultivated for 1 day were harvested, and translating polypeptides were labeled with O-Propargyl-Puromycin (OPP) for 30 min at 37 °C followed by staining with 5 FAM Azide using the Protein Synthesis Assay kit (Cayman Chemical). Then the cells were analyzed by Flow cytometry.
Instrument BD FACSVerseTM

Software
The data were corrected by using BD FACSuiteTM and analyzed by FlowJo v10 (LCC).
Cell population abundance The intensity of 5 FAM was determined by using all cells analyzed by flow cytometry.
Gating strategy
The intensity of 5 FAM was determined by using all cells analyzed. Therefore, gating is not applicable.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
